{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:27Z","timestamp":1781625987567,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) effectively increase hemoglobin levels to treat anemia in patients with chronic kidney disease (CKD). However, there is a paucity of studies on the effect of HIF-PHIs on renal outcomes, such as estimated glomerular filtration rate based on serum creatinine (eGFRcre). Therefore, this study aimed to examine the trajectory of eGFRcre decline following initiation of treatment with HIF-PHI and erythropoiesis-stimulating agents (ESAs) in non-dialysis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective study enrolled non-dialysis patients who were prescribed HIF-PHIs between January 1, 2020 and December 31, 2022. We used five HIF-PHIs approved in Japan. The eGFRcre slope for a year after HIF-PHIs therapy was initiated was compared with that of ESAs. The eGFRcre slope was calculated using a linear mixed-effects model for repeated measures over a year from the time of enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 134 patients: 79 and 55 patients treated with HIF-PHIs and ESAs, respectively. The model adjusting for time, drug (HIF-PHI or ESA), their interaction, age, sex, BMI, and CKD stage showed that the effect on eGFRcre differed between HIF-PHIs and ESAs (\u22122.11\u2009\u00b1\u20090.57\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      per year vs. \u22123.27\u2009\u00b1\u20090.17\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      per year,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.046). Subgroup analysis by CKD stage revealed a difference in the eGFRcre slope between HIF-PHI and ESA only in the stage 4 group (\u22121.89\u2009\u00b1\u20090.44\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      per year vs. \u22123.69\u2009\u00b1\u20090.44\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      per year,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HIF-PHI preserved eGFRcre for a year, suggesting that its effect was superior to that of ESA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00527-1","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T14:45:34Z","timestamp":1766241934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preservation of eGFRcre for 1 year with HIF-PHI in non-dialysis patients: a retrospective observational cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Tomohiro","family":"Aigami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ishigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nonoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Fukudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"7","key":"527_CR1","doi-asserted-by":"publisher","first-page":"e0236132","DOI":"10.1371\/journal.pone.0236132","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, et al. Prevalence of anemia in patients with Chronic Kidney Disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan chronic kidney disease Database (J-CKD-DB). PLoS ONE. 2020, Jul, 20;15(7):e0236132.","journal-title":"PLoS One"},{"issue":"9","key":"527_CR2","doi-asserted-by":"publisher","first-page":"e1223","DOI":"10.34067\/KID.0000000000000204","volume":"4","author":"T Kuragano","year":"2023","unstructured":"Kuragano T, Okami S, Tanaka-Mizuno S, Ohashi Y, Kanda E, Nangaku M, et al. Anemia treatment, hemoglobin variability, and clinical events in patients with nondialysis-dependent CKD in Japan. Kidney360. 2023, Sep, 1;4(9):e1223\u201335.","journal-title":"Kidney360"},{"issue":"2","key":"527_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1440-1797.2008.01065.x","volume":"14","author":"ML Thorp","year":"2009","unstructured":"Thorp ML, Johnson ES, Yang X, Petrik AF, Platt R, Smith DH. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrol (Carlton). 2009, Apr;14(2):240\u201346.","journal-title":"Nephrol (carlton)"},{"issue":"11","key":"527_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019, Sep, 12;381(11):1001\u201310.","journal-title":"N Engl J Med"},{"issue":"11","key":"527_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019, Sep, 12;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"issue":"17","key":"527_CR6","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","volume":"384","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021, Apr, 29;384(17):1589\u2013600.","journal-title":"N Engl J Med"},{"issue":"17","key":"527_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021, Apr, 29;384(17):1601\u201312.","journal-title":"N Engl J Med"},{"issue":"25","key":"527_CR8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021, Dec, 16;385(25):2313\u201324.","journal-title":"N Engl J Med"},{"issue":"25","key":"527_CR9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med. 2021, Dec, 16;385(25):2325\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"527_CR10","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, et al. A Phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the symphony ND study. Kidney Int Rep. 2021, Jul;6(7):1840\u201349.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"527_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","volume":"7","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, Koretomo R, Maeda K, Miyazawa Y, et al. A Phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: symphony hd study. Kidney Dis (basel). 2021, Jul, 5;7(6):494\u2013502.","journal-title":"Kidney Dis (basel)"},{"issue":"10\u201311","key":"527_CR12","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1159\/000518072","volume":"52","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, Phase 3 study. Am J Nephrol. 2021;52(10\u201311):884\u201393.","journal-title":"Am J Nephrol"},{"issue":"10","key":"527_CR13","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","volume":"6","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Yamada T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, et al. Molidustat for Japanese patients with renal anemia receiving dialysis. Kidney Int Rep. 2021, Jul, 23;6(10):2604\u201316.","journal-title":"Kidney Int Rep"},{"key":"527_CR14","doi-asserted-by":"crossref","unstructured":"Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, et al. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022, Aug, 25;8(8): CD013751.","DOI":"10.1002\/14651858.CD013751.pub2"},{"issue":"1","key":"527_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","volume":"18","author":"DS Silverberg","year":"2003","unstructured":"Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transpl. 2003, Jan;18(1):141\u201346.","journal-title":"Nephrol Dial Transpl"},{"issue":"21","key":"527_CR16","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","volume":"361","author":"MA Pfeffer","year":"2009","unstructured":"Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009, Nov, 19;361(21):2019\u201332.","journal-title":"N Engl J Med"},{"issue":"20","key":"527_CR17","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006, Nov, 16;355(20):2085\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"527_CR18","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1093\/ndt\/gfr754","volume":"27","author":"X Yu","year":"2012","unstructured":"Yu X, Fang Y, Liu H, Zhu J, Zou J, Xu X, et al. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transpl. 2012, Aug;27(8):3110\u201319.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"527_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.kint.2019.12.007","volume":"97","author":"S Hasegawa","year":"2020","unstructured":"Hasegawa S, Tanaka T, Saito T, Fukui K, Wakashima T, Susaki EA, et al. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease. Kidney Int. 2020, May;97(5):934\u201350.","journal-title":"Kidney Int"},{"issue":"3","key":"527_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized Phase 3 study. J Am Soc Nephrol. 2021, Mar;32(3):737\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"527_CR21","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, Sch\u00f6mig M, Lizzi F, Reusch M, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transpl. 2021, Sep;36(9):1616\u201328.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"527_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.ajkd.2022.09.014","volume":"81","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Wang Y, Yang H, Sun L, Zhang P, Zhang X, et al. Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2023, Apr;81(4):434\u201345.e1.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"527_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","volume":"104","author":"E Ku","year":"2023","unstructured":"Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al. Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving Global outcomes (KDIGO) controversies conference. Kidney Int. 2023, Oct;104(4):655\u201380.","journal-title":"Kidney Int"},{"issue":"1","key":"527_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National kidney Foundation in collaboration with the us food and drug administration and European medicines agency. Am J Kidney Dis. 2020, Jan;75(1):84\u2013104.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"527_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009, Jun;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"527_CR26","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002, Feb;39(2 Suppl 1):S1\u2013266."},{"issue":"7","key":"527_CR27","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023, Jul;29(7):1867\u201376.","journal-title":"Nat Med"},{"issue":"7","key":"527_CR28","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ejrad.2011.03.045","volume":"81","author":"WJ Yin","year":"2012","unstructured":"Yin WJ, Liu F, Li XM, Yang L, Zhao S, Huang ZX, et al. Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol. 2012, Jul;81(7):1426\u201331.","journal-title":"Eur J Radiol"},{"issue":"12","key":"527_CR29","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cardfail.2023.06.021","volume":"29","author":"BJ Quiram","year":"2023","unstructured":"Quiram BJ, Killian JM, Redfield MM, Smith J, Hickson LJ, Schulte PJ, et al. J Card Fail. 2023, Dec;29(12):1617\u201325.","journal-title":"J Card Fail"},{"key":"527_CR30","doi-asserted-by":"publisher","first-page":"103942","DOI":"10.1016\/j.ebiom.2022.103942","volume":"77","author":"B Wang","year":"2022","unstructured":"Wang B, Li ZL, Zhang YL, Wen Y, Gao YM, Liu BC. Hypoxia and chronic kidney disease. EBioMedicine. 2022, Mar;77:103942.","journal-title":"EBioMedicine"},{"issue":"7","key":"527_CR31","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1097\/01.ASN.0000017223.49823.2A","volume":"13","author":"C Rosenberger","year":"2002","unstructured":"Rosenberger C, Mandriota S, J\u00fcrgensen JS, Wiesener MS, H\u00f6rstrup JH, Frei U, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002, Jul;13(7):1721\u201332.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"527_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/0886022X.2021.1915801","volume":"43","author":"AF Miao","year":"2021","unstructured":"Miao AF, Liang JX, Yao L, Han JL, Zhou LJ. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia\/reperfusion injury by inhibiting inflammation. Ren Fail. 2021, Dec;43(1):803\u201310.","journal-title":"Ren Fail"},{"issue":"6","key":"527_CR33","doi-asserted-by":"publisher","first-page":"F1105","DOI":"10.1152\/ajprenal.00285.2020","volume":"319","author":"M Jiang","year":"2020","unstructured":"Jiang M, Bai M, Lei J, Xie Y, Xu S, Jia Z, et al. Mitochondrial dysfunction and the AKI-to-CKD transition. Am J Physiol Renal Physiol. 2020, Dec, 1;319(6):F1105\u201316.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"527_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ki.2008.350","volume":"74","author":"LG Fine","year":"2008","unstructured":"Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008, Oct;74(7):867\u201372.","journal-title":"Kidney Int"},{"key":"527_CR35","doi-asserted-by":"publisher","first-page":"837249","DOI":"10.3389\/fphar.2022.837249","volume":"13","author":"M Miao","year":"2022","unstructured":"Miao M, Wu M, Li Y, Zhang L, Jin Q, Fan J, et al. Clinical potential of hypoxia inducible factors prolyl hydroxylase inhibitors in treating nonanemic diseases. Front Pharmacol. 2022, Feb, 24;13:837249.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00527-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00527-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00527-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:31:46Z","timestamp":1781623906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00527-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00527-1","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board at Sapporo Medical University approved this study (342\u2013132) and Informed consent was obtained in the form of an opt-out on a website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Yamashita has received payment or honoraria from Kyowa Kirin, Astellas Pharma, Bayer, Torii Pharmaceutical, and Mitsubishi Tanabe Pharma for lectures, presentations, and educational activities. Dr. Yano has received payment or honoraria from Kyowa Kirin and Bayer for lectures, presentations, and educational activities. All other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}